183 related articles for article (PubMed ID: 29185289)
1. Severe Hypocalcemia Following a Single Denosumab Injection.
Cernes R; Barnea Z; Biro A; Zandman-Goddard G; Katzir Z
Isr Med Assoc J; 2017 Nov; 19(11):719-721. PubMed ID: 29185289
[No Abstract] [Full Text] [Related]
2. Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
Saito S; Sugo Y; Tsuburai T; Kurasawa K; Nakamura T; Yoshikata H; Miyagi E; Sakakibara H
J Obstet Gynaecol Res; 2019 Apr; 45(4):908-914. PubMed ID: 30618176
[TBL] [Abstract][Full Text] [Related]
3. Denosumab anf cronic kidney disease: Severe life-threatening hypocalcemia.
Monge Rafael P; Martin de Francisco ÁL; Fernández-Fresnedo G
Nefrologia (Engl Ed); 2018; 38(1):97-98. PubMed ID: 29325673
[No Abstract] [Full Text] [Related]
4. In brief: Severe hypocalcemia with denosumab (Prolia) in chronic kidney disease.
Med Lett Drugs Ther; 2024 Mar; 66(1697):40. PubMed ID: 38412278
[No Abstract] [Full Text] [Related]
5. Hypercalcaemia-induced acute kidney injury in an older patient with osteoporosis treated with alfacalcidol for denosumab-induced hypocalcaemia.
Yamada S; Matsuo M; Tokumoto M; Ooboshi H
Nephrology (Carlton); 2017 Jul; 22(7):572-573. PubMed ID: 28621008
[No Abstract] [Full Text] [Related]
6. Hypocalcaemic tetany occurring post a single denosumab dose in a patient with stage 4 chronic kidney disease, followed by calcium- and calcitriol-induced hypercalcaemia.
Lambe G; Malvathu R; Thomas HM; Graves A
Nephrology (Carlton); 2015 Aug; 20(8):583-4. PubMed ID: 26194986
[No Abstract] [Full Text] [Related]
7. Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease.
Salim SA; Nair LR; Thomas L; Garla V; Palabindala V; Agarwal M; Fülöp T
Am J Med Sci; 2018 May; 355(5):506-509. PubMed ID: 29753381
[TBL] [Abstract][Full Text] [Related]
8. Life-threatening hypocalcaemia associated with denosumab in advanced chronic kidney disease.
Killen JP; Yong K; Luxton G; Endre Z
Intern Med J; 2016 Jun; 46(6):746-7. PubMed ID: 27257154
[No Abstract] [Full Text] [Related]
9. Safety of denosumab in dialysis patients on calcium and vitamin D supplements.
Ullah A; Abdulnabi K; Khalil A; Alexander J; Pai P; Mishra V
Saudi J Kidney Dis Transpl; 2017; 28(1):158-161. PubMed ID: 28098118
[No Abstract] [Full Text] [Related]
10. Denosumab-induced Normocalcemic Hyperparathyroidism in a Woman with Postmenopausal Osteoporosis and Normal Renal Function.
Mazokopakis EE
Curr Drug Saf; 2018; 13(3):214-216. PubMed ID: 29879891
[TBL] [Abstract][Full Text] [Related]
11. [Denosumab in clinical practice : beware before, during and after].
Lamy O; Gonzalez-Rodriguez E; Stoll D; Aubry-Rozier B
Rev Med Suisse; 2017 Apr; 13(559):863-866. PubMed ID: 28727345
[TBL] [Abstract][Full Text] [Related]
12. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
Dave V; Chiang CY; Booth J; Mount PF
Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847
[TBL] [Abstract][Full Text] [Related]
13. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.
Huynh AL; Baker ST; Stewardson AJ; Johnson DF
Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1274-1278. PubMed ID: 27255807
[TBL] [Abstract][Full Text] [Related]
14. Excess of second tumors in denosumab-treated patients: a metabolic hypothesis.
Tovazzi V; Dalla Volta A; Pedersini R; Amoroso V; Berruti A
Future Oncol; 2019 Jul; 15(20):2319-2321. PubMed ID: 31237145
[No Abstract] [Full Text] [Related]
15. [Symptomatic hypocalcaemia on denosumab use].
Baptista Lopes V; Robbrecht D; van Thiel S; van Guldener C
Ned Tijdschr Geneeskd; 2013; 157(29):A6159. PubMed ID: 23859106
[TBL] [Abstract][Full Text] [Related]
16. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
17. Case report: Recurrent severe hypocalcemia secondary to denosumab in a patient with chronic kidney disease.
Correia M; Pereira P; Ferreira CC; Cerqueira M; Almeida DE
Int J Rheum Dis; 2024 Jun; 27(6):e15211. PubMed ID: 38831530
[No Abstract] [Full Text] [Related]
18. Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.
Autio KA; Farooki A; Glezerman IG; Chan A; Schneider CW; Barr HC; Seyboth BM; Kampel LJ; Danila DC; Rathkopf DE; Slovin SF; Scher HI; Morris MJ
Clin Genitourin Cancer; 2015 Aug; 13(4):e305-e309. PubMed ID: 25559408
[No Abstract] [Full Text] [Related]
19. Severe hypocalcemia after denosumab administration in a patient with chronic kidney disease: a case report.
Kouroglou E; Tsiama V; Dionysopoulou S; Gavriiloglou G; Bora M; Belis K; Proikaki S; Savvidis C; Giannou P; Petras D
J Musculoskelet Neuronal Interact; 2023 Jun; 23(2):285-289. PubMed ID: 37259667
[TBL] [Abstract][Full Text] [Related]
20. Hypocalcemia induced by raloxifene.
Vu TD; Varadarajan S; Seeman E; Jerums G; MacIsaac RJ
Curr Drug Saf; 2012 Apr; 7(2):176-8. PubMed ID: 22873502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
